Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Haemophilia A With Factor VIII Inhibitors
Latest Information Update: 17 May 2021
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors Baxter Healthcare Corporation
- 17 Jun 2014 New trial record
- 30 Sep 2013
- 27 Nov 2012